Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06166810

Capture of Healthy Gut Bacteria Associated to High Fiber Diet

The role of the intestinal microbiota on health is now well recognised, and diet is one of the factors influencing the maintenance of a healthy intestinal microbiota. More specifically, the consumption of fruit, vegetables and cereals is associated with good health and, in particular, with an increase in the relative abundance of bacterial groups described as beneficial. To date, a large number of bacterial species in the intestinal microbiota have yet to be isolated and cultivated, which limits the characterisation of their potential health benefits. In order to isolate and cultivate these intestinal bacteria, it is particularly relevant to recruit individuals with a high-fibre diet.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Age range

20 year–50 year

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

Since two decades, numerous studies have been performed to better understand the role of the gut microbiota in health and disease. An imbalance in the intestinal microbiota, known as dysbiosis, is frequently described as a cause of many chronic diseases and metabolic dysfunctions in humans. Among the factors that play an important role in maintaining this balance, diet plays a predominant role. More specifically, the consumption of fruit, vegetables and cereals is associated with good health and, in particular, with an increase in the relative abundance of bacterial groups described as beneficial. Modulating the intestinal microbiota via the or directly by providing these beneficial bacteria (next generation probiotics NGPs) is therefore a possible promising approach for the prevention and/or treatment of pathologies. To date, a large number of bacterial species in the intestinal microbiota have yet to be isolated and cultivated, which limits the characterization of their potential health benefits. Having strains that can be isolated and cultured is an essential step in phenotyping and characterization. In order to isolate and cultivate these intestinal bacteria, it is particularly important to recruit individuals with a high-fiber diet. In this context, a positive selection of donors, based on their dietary profiles highly enriched in fiber, is essential. In this study, the aim is to identify in silico unprecedented potentially new beneficial gut bacteria, and isolate, culture and characterize these bacterial species for their potential. This will be an innovative approach, using culturomics tools guided by metagenomics to isolate them. To do this, the fecal samples of 10 healthy volunteers will be collected with a regular and diversified intake of fruit, vegetables and cereals, which encourage the growth of beneficial micro-organisms and increase the richness of the intestinal microbiota.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy adult subjects ;
  • Age between 20 and 50 (limits included) ;
  • BMI between 18.5 and 25 kg/m2 (excluding limits) ;
  • Consumption of more than 5 portions of fruit and vegetables a day;
  • Intake of at least 25g of dietary fibre per day;
  • A varied diet with little processed food.

Exclusion criteria

  • Antibiotics and/or transit modulators taken in the 3 months prior to sampling;
  • Known pathologies;
  • Current treatment;
  • History of digestive surgery having an impact on the microbiota, deemed incompatible with the study (bariatric surgery);
  • Consumption of food supplements based on protein preparations, probiotics or prebiotics;
  • Smoking (even occasionally);
  • Alcohol consumption > 2 glasses (i.e. 20 g) per day;
  • Intense sporting activity;
  • Pregnant or breast-feeding women;
  • Persons under legal protection (curatorship, guardianship, etc.);
  • Volunteers taking part in another intervention study;
  • Persons refusing to be registered on the French Ministry of Health's Fichier National des Volontaires Sains (National Register of Healthy Volunteers);
  • Subject not affiliated to the social security system;
  • Subject in a period of exclusion from a previous study or having received a total amount of compensation exceeding 6000 euros over the 12 consecutive months prior to the start of the trial (after verification in the Fichier des Volontaires pour la Recherche Biomédicale).

Treatment and study plan

Primary outcomes

  1. Isolation and culture of one isolate from each target species

    Time frame: Up to 3 years

    Successful isolation and culture of at least one isolate from each target species previously identified through metagenomic data analyses.

Secondary outcomes

  1. metagenomic profiles in relation to dietary profiles

    Time frame: Up to 3 years

    To obtain metagenomic profiles using shotgun sequencing of the gut microbiota (bacterial species), in relation to dietary profiles

  2. growth capacity of the isolates

    Time frame: Up to 3 years

    To characterize the growth (growth monitoring by optical density) of the isolates of interest.

  3. Functional potential of the isolates

    Time frame: up to 3 years.

    To characterize the genomic features of the isolates of interest (functional potential through genome annotation).

  4. Phenotypic caracterization of the isolates

    Time frame: Up to 3 years

    To characterize phenotypically the isolates of interest by API gallery.

Study contacts

Contact information is provided by the study sponsor or research team.

Aurélie CAILLE, MSc

CONTACT

[email protected]

04 73 75 42 73

Nathalie MEUNIER, PhD

CONTACT

[email protected]

04 73 75 42 73

Sponsors and collaborators

Lead sponsor

Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement

Other

Collaborators

  • Centre de Recherche en Nutrition Humaine d'Auvergne

Registry information

Official study title

In Silico and in Vitro Targeting of Healthy Gut Bacteria With Fiber Degrading Metabolic Potential

Acronym: iTARGET

Important dates

Study start
2023
Primary completion
2025
Study completion
2026
First posted
Dec 12, 2023
Registry last updated
Jun 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.